Trials / Completed
CompletedNCT01164345
Mozobil for Autologous Stem Cell Mobilization
Plerixafor (Plerixafor AMD 3100) + Recombinant Human G-CSF (rhG-CSF) for Autologous Peripheral Blood Stem Cell Transplantation (AutoSCT) in Hard to Mobilise Patients: a Phase IIB Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Sheba Medical Center · Other Government
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate Plerixafor (MOZOBIL) plus recombinant human G-CSF (G-CSF) efficiency in mobilizing sufficient number of stem cells from Lymphoma (NHL and HL) patients for autologous transplantation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Plerixafor | Plerixafor (mozobil) 240 mcg/kg SC will be administered in the evening, 10 hours prior to initiation of apheresis.G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis. |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2010-07-16
- Last updated
- 2015-12-03
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01164345. Inclusion in this directory is not an endorsement.